NCT02597036 A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT02593786 A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT02587962 Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02587598 Study of INCB053914 in Subjects With Advanced Malignancies Status TERMINATED Phase PHASE1/PHASE2
NCT02559492 Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT02556463 A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors Status TERMINATED Phase PHASE1
NCT02546531 Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Status COMPLETED Phase PHASE1
NCT02537561 Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Status WITHDRAWN Phase PHASE1
NCT02536183 A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Status TERMINATED Phase PHASE1
NCT02533674 Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02521844 A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02517398 MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02506517 A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene Status COMPLETED Phase PHASE2
NCT02503774 MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. Status COMPLETED Phase PHASE1
NCT02503423 Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02500199 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Status UNKNOWN Phase PHASE1
NCT02499224 Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy Status COMPLETED Phase PHASE1
NCT02498912 Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02496949 A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors Status COMPLETED Phase PHASE1